Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Artículo en Inglés | MEDLINE | ID: mdl-39417970

RESUMEN

PURPOSE: Differentiation of the cause of left ventricular hypertrophy (LVH) is challenging in cases with co-existing hypertension. CMR offers assessment of diffuse myocardial abnormalities via T1 mapping with extracellular volume fraction (ECV) and macroscopic fibrosis via late gadolinium enhancement imaging (LGE). The goal of the study was to understand if CMR parameters can differentiate hypertensive cardiomyopathy (HC) from cardiac amyloidosis (CA) in patients with hypertension and heart failure, using endomyocardial biopsy (EMB) as the gold standard. METHODS: We retrospectively analyzed patients with hypertension, LVH, and heart failure undergoing EMB due to uncertain diagnosis. CMR parameters including cine, LGE characteristics, T1 mapping, and ECV were analyzed. RESULTS: A total of 34 patients were included (mean age 66.5 ± 10.7 years, 79.4% male). The final EMB-based diagnosis was HC (10, 29%), light chain (AL) CA (7, 21%), and transthyretin (ATTR) CA (17, 50%). There was a significant difference in subendocardial LGE (p = 0.03) and number of AHA segments with subendocardial LGE (p = 0.005). The subendocardial LGE pattern was most common in AL-CA (85.7%) and African American with HC (80%). ECV elevation (≥ 29%) was present in all patients with CA (AL-CA: 57.6 ± 5.2%, ATTR-CA: 59.1 ± 15.3%) and HC (37.3 ± 4.5%). CONCLUSIONS: Extensive subendocardial LGE pattern is not pathognomonic for CA but might also be present in African American patients with longstanding or poorly controlled HTN. The ECV elevation in HC with HF might be more significant than previously reported with an overlap of ECV values in HC and CA, particularly in younger African American patients.

2.
Cureus ; 16(8): e67847, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-39323700

RESUMEN

Cardiac arrest during pregnancy does not occur infrequently and is influenced by obstetric and non-obstetric factors. The patient described in this case report is a pregnant woman who suffered a leg injury that required urgent surgical repair. Moments prior to that procedure, the fetus experienced extreme bradycardia on fetal heart tone monitoring. An emergent cesarean section was performed, which was followed by the patient suffering cardiac arrest secondary to an acutely provoked pulmonary embolism. The patient underwent mechanical thrombectomy followed by EkoSonic endovascular system (EKOS) therapy, which was then complicated by a subcapsular hematoma. The patient ultimately had an inferior vena cava (IVC) filter placed, was started on oral anticoagulation, and eventually recovered with discharge to her home with her newborn infant. This report aims to discuss this critical case of obstetric cardiac arrest, detailing the emergent response, clinical management, challenges faced during resuscitation, and subsequent outcomes. Through this report, we seek to contribute to the growing body of knowledge on effectively managing cardiac emergencies in pregnancy, emphasizing interdisciplinary coordination and tailored interventions to enhance survival and recovery in this high-risk group.

3.
Acta Radiol ; 65(6): 588-600, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38619912

RESUMEN

The crista terminalis is an anatomical structure localized on the posterolateral wall of the right atrium (RA). We performed a systematic review of the literature and meta-analysis concerning cases of unusual prominent crista terminalis mimicking RA mass. Moreover, we described the differential diagnosis of cardiac masses with the use of echocardiography, computed tomography, and cardiac magnetic resonance (CMR). We also emphasize the potential importance of this structure in electrophysiological procedures, including its role in exaggerated arrhythmias. Prominent crista terminalis may be a potential obstacle during invasive cardiac procedures or catheter ablation target. In analyzed cases, the crista terminalis was often erroneously interpreted as pathologic and at first confused with a thrombus or tumor during transthoracic echocardiography examination. The correct final diagnoses were mostly made with used transesophageal echocardiography or CMR. The most important imaging findings suggestive of prominent crista terminalis rather than tumor were a similar echogenicity/intensity with adjacent myocardium, the location on posterolateral wall of the RA, the phasic change in size, and no enhancement after contrast injection. We describe up to date and detailed imaging features for the differential diagnostics of selected intracardiac masses using various imaging techniques, including multimodality cardiac imaging. Familiarity with the anatomy and the imaging findings of the prominent crista terminalis will reduce misdiagnosis and avoid additional tests and unwarranted clinical interventions, while in patients considered for invasive cardiac procedures it might increase their efficacy and safety.


Asunto(s)
Atrios Cardíacos , Neoplasias Cardíacas , Humanos , Diagnóstico Diferencial , Atrios Cardíacos/diagnóstico por imagen , Atrios Cardíacos/anomalías , Neoplasias Cardíacas/diagnóstico por imagen , Imagen por Resonancia Magnética/métodos , Ecocardiografía/métodos
4.
PLoS One ; 18(12): e0295519, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-38117807

RESUMEN

OBJECTIVES: The study sought to assess the prognostic significance of nonischemic myocardial fibrosis (MF) on cardiovascular magnetic resonance (CMR)-both macroscopic MF assessed by late gadolinium enhancement (LGE) and diffuse microscopic MF quantified by extracellular volume fraction (ECV)-in patients with structurally normal hearts. BACKGROUND: The clinical relevance of tissue abnormalities identified by CMR in patients with structurally normal hearts remains unclear. METHODS: Consecutive patients undergoing CMR were screened for inclusion to identify those with LGE imaging and structurally normal hearts. ECV was calculated in patients with available T1 mapping. The associations between myocardial fibrosis and the outcomes of all-cause mortality, new-onset heart failure [HF], and an arrhythmic outcome were evaluated. RESULTS: In total 525 patients (mean age 43.1±14.2 years; 30.5% males) were included. Over a median follow-up of 5.8 years, 13 (2.5%) patients died and 18 (3.4%) developed new-onset HF. Nonischemic midwall /subepicardial LGE was present in 278 (52.9%) patients; isolated RV insertion fibrosis was present in 80 (15.2%) patients. In 276 patients with available T1 mapping, the mean ECV was 25.5 ± 4.4%. There was no significant association between LGE and all-cause mortality (HR: 1.36, CI: 0.42-4.42, p = 0.61), or new-onset HF (HR: 0.64, CI: 0.25-1.61, p = 0.34). ECV (per 1% increase) correlated with all-cause mortality (HR: 1.19, CI: 1.04-1.36, p = 0.009), but not with new-onset HF (HR: 0.97, CI: 0.86-1.10, p = 0.66). There was no significant association between arrhythmic outcomes and LGE (p = 0.60) or ECV (p = 0.49). In a multivariable model after adjusting for covariates, ECV remained significantly associated with all-cause mortality (HR per 1% increase in ECV: 1.26, CI: 1.06-1.50, p = 0.009). CONCLUSION: Nonischemic LGE in patients with structurally normal hearts is common and does not appear to be associated with adverse outcomes, whereas elevated ECV is associated with all-cause mortality and may be an important risk stratification tool.


Asunto(s)
Cardiomiopatías , Insuficiencia Cardíaca , Masculino , Humanos , Adulto , Persona de Mediana Edad , Femenino , Miocardio/patología , Medios de Contraste , Volumen Sistólico , Imagen por Resonancia Cinemagnética , Gadolinio , Cardiomiopatías/patología , Fibrosis , Medición de Riesgo , Valor Predictivo de las Pruebas
5.
Am J Vet Res ; 83(10)2022 08 02.
Artículo en Inglés | MEDLINE | ID: mdl-35905145

RESUMEN

OBJECTIVE: To assess whether cardiac MRI or various biomarkers can be used to detect myocardial ischemia and fibrosis in dogs with cardiomegaly secondary to myxomatous mitral valve disease (MMVD). ANIMALS: 6 dogs with cardiomegaly secondary to naturally occurring stage B2 MMVD being treated only with pimobendan with or without enalapril and 6 control dogs with no cardiac disease. All dogs were ≥ 5 years old with no systemic illness. PROCEDURES: Serum cardiac troponin I and concentrations were measured, and dogs were anesthetized for cardiac MRI with ECG-triggered acquisition of native T1- and T2-weighted images. Gadolinium contrast was administered to evaluate myocardial perfusion and late gadolinium enhancement (LGE). Mean T1 and T2 values and regions of LGE were measured with dedicated software. Extracellular volume (ECV) was estimated on the basis of Hct and T1 values of myocardium and surrounding blood. Subjective analysis for myocardial perfusion deficits was performed. RESULTS: Dogs with MMVD had significantly (P = .013) higher cardiac troponin I concentrations than control dogs, but galectin-3 concentrations did not differ (P = .08) between groups. Myocardial fibrosis was detected in 4 dogs with MMVD and 3 control dogs; no dogs had obvious myocardial perfusion deficits. Native T1 and T2 values, postcontrast T1 values, and ECV values were not significantly different between groups (all P > .3). CLINICAL RELEVANCE: Results suggest that some dogs with cardiomegaly secondary to MMVD may not have clinically relevant myocardial fibrosis.


Asunto(s)
Enfermedades de los Perros , Enfermedades de las Válvulas Cardíacas , Isquemia Miocárdica , Animales , Cardiomegalia/tratamiento farmacológico , Cardiomegalia/veterinaria , Medios de Contraste , Enfermedades de los Perros/diagnóstico por imagen , Enfermedades de los Perros/etiología , Perros , Fibrosis , Gadolinio , Enfermedades de las Válvulas Cardíacas/veterinaria , Imagen por Resonancia Magnética/métodos , Imagen por Resonancia Magnética/veterinaria , Válvula Mitral , Isquemia Miocárdica/diagnóstico por imagen , Isquemia Miocárdica/etiología , Isquemia Miocárdica/veterinaria , Troponina I
6.
Heart Fail Clin ; 18(3): 455-478, 2022 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-35718419

RESUMEN

Cardiovascular (CV) events are an increasingly common limitation of effective anticancer therapy. Over the last decade imaging has become essential to patients receiving contemporary cancer therapy. Herein we discuss the current state of CV imaging in cardio-oncology. We also provide a practical apparatus for the use of imaging in everyday cardiovascular care of oncology patients to improve outcomes for those at risk for cardiotoxicity, or with established cardiovascular disease. Finally, we consider future directions in the field given the wave of new anticancer therapies.


Asunto(s)
Antineoplásicos , Enfermedades Cardiovasculares , Neoplasias , Antineoplásicos/efectos adversos , Cardiotoxicidad/diagnóstico por imagen , Cardiotoxicidad/etiología , Enfermedades Cardiovasculares/diagnóstico por imagen , Ecocardiografía , Humanos , Imagen por Resonancia Magnética , Oncología Médica , Neoplasias/complicaciones , Neoplasias/diagnóstico por imagen , Neoplasias/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA